1. Home
  2. LZM vs LXEO Comparison

LZM vs LXEO Comparison

Compare LZM & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lifezone Metals Limited

LZM

Lifezone Metals Limited

HOLD

Current Price

$4.25

Market Cap

352.5M

ML Signal

HOLD

Logo Lexeo Therapeutics Inc.

LXEO

Lexeo Therapeutics Inc.

HOLD

Current Price

$4.89

Market Cap

396.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
LZM
LXEO
Founded
2021
2017
Country
Isle of Man
United States
Employees
N/A
N/A
Industry
Metal Mining
Sector
Basic Materials
Exchange
Nasdaq
Nasdaq
Market Cap
352.5M
396.5M
IPO Year
2023
2023

Fundamental Metrics

Financial Performance
Metric
LZM
LXEO
Price
$4.25
$4.89
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
9
Target Price
$7.00
$18.44
AVG Volume (30 Days)
360.2K
818.9K
Earning Date
03-19-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
39.81
EPS
N/A
N/A
Revenue
N/A
$654,000.00
Revenue This Year
$86.37
N/A
Revenue Next Year
$202.49
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.00
$3.99
52 Week High
$6.40
$10.99

Technical Indicators

Market Signals
Indicator
LZM
LXEO
Relative Strength Index (RSI) 52.86 47.30
Support Level $4.06 $4.39
Resistance Level $4.29 $5.38
Average True Range (ATR) 0.26 0.26
MACD -0.01 -0.04
Stochastic Oscillator 47.59 18.56

Price Performance

Historical Comparison
LZM
LXEO

About LZM Lifezone Metals Limited

Lifezone Metals Ltd seeks to support the clean energy transition through the licensing of Hydromet Technology as an alternative to smelting and metals refining. Its business comprises three segments: Metals extraction and refining for developing and operating a vertically integrated base metal operation in the northwest region of Tanzania, and Intellectual property licensing comprises patents residing with and managed by the subsidiary and corporate. Geographically, the company operates in South Africa, Australia, and the rest of the world. The majority of its revenue is generated from Australia.

About LXEO Lexeo Therapeutics Inc.

Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.

Share on Social Networks: